HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia by Stanevicha, Valda et al.
R340
Introduction
According to data from the Latvian Rheumatic Disease
Patient Registry, 1298 children (born between 1984 and
2002) suffer from rheumatic diseases, of which rheumatic
fever (RF) is the third most frequent. RF is an autoimmune
connective tissue disease that develops after group A
beta haemolytic streptococcal infection. The typical
feature of the disease is the formation of autoantibodies
against the connective tissue structures in the heart, syn-
ovial tissue, and neurons in the central nervous system.
Rheumatic heart disease (RHD) is one of the most severe
consequences of RF and is the main cause of acquired
valvular RHD in the world [1–9]. In Latvia, since 1991 the
number of RF cases in children under the age of 18 has
increased, reaching an incidence of 7.5/100,000 in 1998.
From 1999 to 2002, the incidence was stable, at
2.1/100,000 children.
Several authors have documented the familial occurrence
of the disease [10–12], and it has been concluded that
susceptibility to RF is inherited as a single recessive gene
[13]. More substantial evidence for a genetic association
was provided by Khanna and associates, who reported that
B-cell alloantigens, designated D8-17, were present in
99% of patients with RF [13]. Further support for the role
of genetic factors in susceptibility was provided by studies
on the associations of this disease with inheritance of the
HLA major histocompatibility antigens [14–23]. Several
studies have suggested that genetic susceptibility to RF
and RHD is linked to HLA class II alleles [20,24–34].
AVR = aortal valve regurgitation; MVL = multivalvular lesion; MVR = mitral valve regurgitation; OR = odds ratio; PCR–SSP = polymerase chain
reaction with amplification with sequence-specific primers; PCR = polymerase chain reaction; RF = rheumatic fever; RHD = rheumatic heart
disease.
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Abstract
Genetic control of immune reactions has a major role in the
development of rheumatic heart disease (RHD) and differs
between patients with rheumatic fever (RF). Some authors think
the risk of acquiring RHD is associated with the HLA class II DR
and DQ loci, but other views exist, due to the various HLA-typing
methods and ways of grouping cases. Our goal was to
determine the relations between HLA class II alleles and risk of or
protection from RF in patients with relatively homogeneous
clinical manifestations. A total of 70 RF patients under the age of
18 years were surveyed in Latvia. HLA genotyping of DRB1*01
to DRB1*18 and DQB1*0201-202, *0301-305, *0401-402,
*0501-504, and *0601-608 was performed using polymerase
chain reaction sequence-specific primers. Data for a control
group of 100 healthy individuals typed for HLA by the same
method were available from the databank of the Immunology
Institute of Latvia. Of the RF patients, 47 had RHD and 8 had
Sydenham’s chorea. We concluded that HLA class II DRB1*07-
DQB1*0401-2 and DRB1*07-DQB1*0302 could be the risk
alleles and HLA class II DRB1*06 and DQB1*0602-8, the
protective ones. Patients with mitral valve regurgitation more
often had DRB1*07 and DQB1*0401-2, and patients with
multivalvular lesions more often had DRB1*07 and DQB1*0302.
In Sydenham’s chorea patients, the DQB1*0401-2 allele was
more frequent. Genotyping control showed a high risk of RF and
RHD in patients with DRB1*01-DQB1*0301-DRB1*07-
DQB1*0302 and DRB1*15-DQB1*0302-DRB1*07-DQB1*0303.
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However, there has been an apparent discrepancy con-
cerning the nature of susceptibility or protective alleles
[27]. One explanation is that most investigations used
serological HLA genotyping methods that were less than
accurate, leading to false results and failure to discrimi-
nate between allele subgroups.
Genetic associations are more likely to be detected in clin-
ically homogeneous groups of patients, and therefore it is
important to separate carditis patients from patients
without carditis [27]. In studies in which RF patients with
carditis were analysed separately from those without
carditis, or in which only RHD patients mostly with mitral
valve disease were studied, the reported HLA associa-
tions were rather similar [20,25–28,34,35].
We analysed the case histories of all white children under
18 years of age living in Latvia who had been affected by
RF, with the aim to determine risk/protective alleles for RF
and RHD. The HLA class II alleles were determined using
polymerase chain reaction (PCR) in clinically homoge-
neous patient groups: RF patients with or without carditis
and in patients with a diagnosis of an RHD — mitral valve
regurgitation (MVR), mitral and aortal valve regurgitation or
multivalvular lesion (MVL), and aortal valve regurgitation
(AVR), and also cases of Sydenham’s chorea.
Materials and methods
Subjects
The study included 70 white children (48 boys [68.5%]
and 22 girls [31.4%]) in Latvia under the age of 18 (born
between 1984 and 2002) who had RF. Of these, 23
(32.8%) were less than 7 years old and 47 (67.1%) were
7 or older. The RF diagnosis was confirmed according to
Jones criteria. Eight RF patients had Sydenham’s chorea.
As a result of RF, 47 patients (67.1%) had developed
RHD. Cardiac valve damage was diagnosed by echocar-
diography and/or heart catheterisation. RHD patients were
further split into groups with MVR (n=24; 34.3%), AVR
(n=3; 4.3%), and MVR+AVR or MVL (n=20; 28.6%).
Only 23 of the patients (32.8%) had fully recovered by the
age of 18. Recurrence of RF was recorded for 15% of the
patients because they had not received prolonged peni-
cillin treatment. Data for healthy individuals (n=100) were
obtained from the Databank of the Immunology Institute of
Latvia. The control individuals were free of autoimmune
disease and had no family history of RF. In both groups
(RF patients and healthy individuals), HLA class II alleles
were determined by PCR.
DNA isolation
Genomic DNA was extracted from proteinase-K-treated
peripheral blood leukocytes using the routine salt-off
method. The DNA was stored in TE buffer (10ml
Tris–HCl, pH 7.5, and 2ml 0.5M Na2 EDTA per litre of dis-
tilled water). The DNA obtained was used immediately for
genotyping or was stored at –20°C. The DNA concentra-
tion, around 100–200µg/ml, was determined by fluores-
cence with a DNA fluorimeter [36].
HLA-DR and -DQ genotyping by PCR
Low-resolution HLA-DR typing for DRB1* 01 to 18 and for
DQB1*0201-202, *0301-305, *0401-402, *0501-504,
and *0601-608 was performed by PCR with amplification
with sequence-specific primers (PCR–SSP) [37]. The reac-
tion mixture (15µl) included 1µl DNA, 1.5µl PCR buffer
[50mM KCl, 1.5mM MgCl2, 10mM Tris-HCl, (pH 8.3)], 0.6µl
dNTPs (25mmol/l), 1.0µl specific primers (0.2mmol/l), and
0.5U of the Taq DNA polymerase (Promega). In addition,
the internal positive control primer pair C3 and C5 was
included in all reaction mixtures at a concentration one-fifth
that of the allele- and group-specific primers.
The reaction mixture was subjected to 35 amplification
cycles, each consisting of denaturation at 94°C (60s), fol-
lowed by one cycle, annealing at 94°C (20s), 67°C (2s)
followed by seven cycles and extension at 93°C (5s), 65°C
(4s), with a final extension in step with 28 cycles.  PCR
products were visualized by agarose-gel electrophoresis.
After addition of 2M loading buffer, the PCR reaction mix-
tures were loaded in agarose gels prestained with ethidium
bromide (0.5µk/ml gel). Gels were run for 15 min at
10 V/cm gel in 0.5mM TBE (0.89 M Tris, 0.89 M Boric acid
and 0.02 M EDTA in aqueous solution) buffer and then
examined under UV illumination and recorded [15,38–40].
Statistical
The HLA-DRB1 and DQB1 frequency of each allele and
genotype was compared between the patients and the
controls using the chi-square test. The P value and odds
ratio (OR) were calculated using EPI INFO software,
version 06, with 95% confidence intervals and Fisher
exact correction for small numbers [41].
Results
Frequencies of DRB1* and DQB1* alleles in RF patients
and control subjects
In RF patients, HLA class II DRB1*07 (OR=4.18,
P<0.01), DQB1*0302 (OR=3.13, P<0.0002), and
DQB1*0401-2 (OR=4.33, P<0.0001) alleles were
found more frequently than in the control group, while the
DRB1*06 (OR=0.18, P<0.0023), DQB1*0602-8
(OR=0.4,  P<0.0127), and DQB1*0501 (OR=0.26,
P<0.0027) alleles were less frequent (Tables 1 and 2).
Frequencies of DRB1 and DQB1 alleles in RF, RHD, and
Sydenham’s chorea patients compared with control
subjects
In the homogeneous patient groups, DRB1*07 had the
highest OR in all RF groups (Table 3): patients with no
acquired valvular heart disease developing after RF carditis
(OR=7.35,  P<0.001), MVR patients (OR=4.45,Arthritis Research & Therapy    Vol 5 No 6 Stanevicha et al.
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P<0.03), MVL patients (OR=5.44, P<0.01), and Syden-
ham’s chorea patients (OR=11.31, P<0.002). The least
frequent allele was DRB1*06 (OR=0.18, P<0.0023). The
DQB1 allele frequencies differed for RHD patients with
MVR and MVL: DQB1*0401-2 (OR=8.20, P<0.001) was
more common in MVR patients and DQB1*0302
(OR=4.18, P<0.001) in MVL patients (Table 3). In Syden-
ham’s chorea patients, a high frequency of DQB1*0401-2
(OR=6.36, P<0.005) was found.
DRB1* and DQB1* genotypes associated with RF
patients
The strongest associations between DRB1* alleles and
RF patients were for DRB1*01-07 (OR=8.57, P<0.05),
DRB1*15-07 (OR=2.86, P<0.02), DRB1*04-05
(OR=3.57,  P<0.04), and DRB1*05-07 (OR=2.86,
P<0.02) (Table 4). The DRB1*03-06 allele (OR=0.48,
P<0.01) had the lowest OR.
Common alleles associated with RF are: DQB1*0301-0302
(OR=5.44,  P<0.05), DQB1*0302-0303 (OR=4.43,
P<0.02), DQB1*0302-0601 (OR=2.91,  P<0.01), and
DQB1*0302-0602-8 (OR=2.19, P<0.01) (Table 5). The
lowest allele frequencies in RF patients were observed for
DQB1*0201-2-0201-2 (OR=0.28, P<0.001) and
DQB1*0303-0602-8 (OR=0.22, P<0.01).
Discussion
HLA associations with RF and RHD have been frequently
investigated, but there is no unanimity of opinion about the
Table 1
Frequencies of DRB1* alleles in RF patients and healthy controls
DRB1* allele RF (n = 140) % Controls (n = 200) % Odds ratio P
*01 24 17 26 13 0.17 <0.643
*15 27 19 44 22 0.88 <0.3603
*03(*17;*18) 18 13 22 11 1.17 <0.184
*04 18 13 24 12 0.017 <0.305
*05(*11;*12) 30 21 33 16.5 1.3 <0.1288
*06(*13;*14) 4 3 28 14 0.18 <0.0023
*07 11 8 4 2 4.18 <0.01
*08 3 2 12 6 0.6** <0.403
* 0 9 4321 1.81** <0.495
*10 1 0.7 5 2.5 0.28** <0.252
**Confield not accurate. Extract limits preferred. RF, rheumatic fever.
Table 2
Frequencies of DQB1* alleles in RF patients and healthy controls
DQB1* allele RF (n = 140) % Controls (n = 200) % Odds ratio P
*0201-2 17 12 32 16 0.76 <0.306
*0301 31 22 39 19.5 1.14 <0.29
*0302 25 18 13 6.5 3.13 <0.0002
*0303 7 5 13 6.5 0.77 <0.624
*0304 1 0.7 2 1 Undefined Undefined
*0305 1 0.7 – – Undefined Undefined
*0401-2 19 14 7 3.5 4.33 <0.0001
*0501 4 3 22 11 0.26** <0.0027
*0502-4 2 1 12 6 0.23** < 0.03
*0601 11 8 11 5.5 1.43 <0.053
*0602-8 22 16 49 24.5 0.4 <0.0127
**Confield not accurate. Extract limits preferred. RF, rheumatic fever.association of specific alleles in connection with the
disease [20,32,33,35]. One reason for this discrepancy
might be the use of old HLA genotyping methods [27].
Besides the technical issues, it has also been suggested
that it is necessary to distinguish clinically homogeneous
patient groups, for example, patient groups with and
without rheumatic carditis, proved RHD, or Sydenham’s
chorea [27,33]. When patients have been divided into
clinically homogeneous patient groups, no differences
between ethnic groups have been found, with the
DRB1*0701, DRB1*0301, and DQB1*0201 alleles being
found at similar frequencies [18,21,32,42,43]. In medical
Available online http://arthritis-research.com/content/5/6/R340
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Table 3
Frequencies of DRB1 and DQB1 alleles in RF and RHD patients compared with control subjects
Group (n = 140) DRB1*06 DRB1*07 DQB1*0302 DQB1*0401-2
All RF (n = 140) gf(P) + OR/χ2 (0.0023) 0.18/11.96 (0.01) 4.18/6.68 (0.001) 3.13/10.67 (0.015) 4.33/11.79
MVR (n = 48) gf(P) + OR/χ2 0.15 (0.03) 4.45/4.95 1.09 (0.001) 8.20/21.59
MVL (n = 40) gf(P) + OR/χ2 0.18 (0.01) 5.44/6.59 (0.001) 4.18/10.21 1.25
Sydenham’s chorea gf(P) + OR/χ2 0 (0.002)11.31/13.19 1.79 (0.005) 6.36/7.17
(n = 16)
without RHD (n = 46) gf(P) + OR/χ2 0.31 (0.001) 7.35/11.65 (0.005) 3.50/7.81 (0.01) 4.14/6.78
Control subjects (n = 200) gf 0.14 0.02 0.07 0.04
Boldface type highlights statistically significant associations for patients vs controls. gf (gene frequency) P (probability), OR (odds ratio), and
Mantel–Hanszel values (χ2) are reported only for significant associations (P < 0.05). n = number of haplotypes (e.g. 140 haplotypes from 70
individuals). The nature of valve lesions was not reported for two patients. MVL, multivalvular lesions; MVR, mitral valve regurgitation; RF, rheumatic
fever; RHD, rheumatic heart disease.
Table 4
Significant association of HLA-DRB1 genotypes with predisposition/protection in RF patients
DRB1 RF (n = 70) % Controls (n = 100) % Odds ratio P (Fisher)
*01/*07 6 8.6 1 1 8.57 <0.05
*15/*03 6 8.6 2 2 4.29 <0.05
*15/*07 2 2.9 1 1 2.86 <0.02
*03/*06 1 1.4 3 3 0.48 <0.01
*04/*05 5 7.1 2 2 3.57 <0.04
*05/*07 2 2.9 1 1 2.86 <0.02
Boldface type highlights statistically significant associations for patients vs controls. RF, rheumatic fever.
Table 5
Significant association of HLA-DQB1 genotypes with predisposition/protection in RF patients
DQB1 RF (n = 70) % Controls (n = 100) % Odds ratio P (Fisher)
*0201-2/*0201-2 1 1.4 3 3 0.28 <0.001
*0201-2/*0602-8 4 5.7 8 8 0.71 <0.34
*0301/*0302 7 10 2 2 5.44 <0.05
*0302/*0303 3 4.3 1 1 4.43 <0.02
*0302/*0601 2 2.9 1 1 2.91 <0.01
*0302/*0602-8 3 4.3 2 2 2.19 <0.01
*0303/*0602-8 1 1.4 6 6 0.22 <0.01
Boldface type highlights statistically significant associations for patients vs controls. RF, rheumatic fever.publications, there is no unanimity of opinion about
whether HLA class II alleles differ with the ethnic origin of
the patients, but this may be connected to the use of dif-
ferent methods of typing HLA alleles.
The data in our investigations were obtained by investigat-
ing RF and RHD patients classified into clinically homoge-
neous patient groups. We found that the HLA class II
DRB1*07, DQB1*0401-2, and DQB1*0302 alleles were
risk factors for acquiring RF and RHD. The DRB1*07
allele was common and had a comparatively high fre-
quency of incidence in patients with RF (Tables 1 and 3).
This suggests that DRB1*07 could be a risk allele for RF
and RHD. Our data on the high frequency of DRB1*07 in
white patients differs from data on Brazilian patients,
where HLA-DR7 was detected in the mulatto group of
patients [20,44]. In our study, the HLA II allele DRB1*07
was rather frequent in white RF patients, both with and
without permanent acquired valvular heart disease.
The HLA class II allele DQB1*0401-2 was found more
often in MVR patients, and DQB1*0302 in MVL patients.
Thus, it can be assumed that HLA-DQ genes control the
risk of development of RHD, both MVL and MVR. This
observation confirms previous findings for RHD patients in
Japan [32]. Our data obtained using the PCR–SSP
method suggests that a risk of developing RHD exists for
the carrier DQ allele exists in Brazil and Japan, as well as
in Latvia.
However, both the DQB1*0401-2 and *0302 allele fre-
quencies were significantly elevated in the RF patient
group and in patients who did not develop permanent
valvular heart disease.
The genotyping showed that a high risk of acquiring RF
and developing RHD was associated with DRB1*01-
DQB1*0301-DRB1*07-DQB1*0302 and DRB1*15-
DQB1*0302-DRB1*07-DQB1*0303. This, however, is
only a supposition, and further experiments with a larger
group will be necessary to establish whether it is correct.
Protective HLA class II alleles are as important as the risk
alleles. Alleles that can be designated protective include
DRB1*03-*06, DQB1*0201-2-*0201-2, and DQB1*0303-
*0602-8. Higher protection against RF and RHD is pro-
vided by the allele genotype DRB1*06-DQB1*0602-8
(Table 6).
Among the alleles found to be protective in our study,
DQB1*0602-8 is most often mentioned in the literature
[20,26,27,29]. Several risk/protective HLA class II sub-
alleles can be misperceived as other suballeles not con-
nected with RF and RHD. Therefore it is important to
determine genotypes [45–47].
HLA alleles regulate the immune response to infections
[48,49], binding and presenting autoantigens with different
affinities and regulating selection of T cells, and at the same
time they themselves can serve as target autoantigens
[50–52]. Different autoimmune peptide presentations with
protective or risk alleles are very important in the develop-
ment and research of the pathogenesis of autoimmunity.
The basis of autoimmune processes that contribute to the
development of RHD is T-cell molecular mimicry between
streptococcal and heart proteins. RHD is initiated by
certain serotypes connected with group A streptococcus
M protein. Guilherme and colleagues suggest that M5
peptide causes severe RHD in patients who have HLA-
DRB1*07 combined with severe RHD [53]. In our study,
patients with severe RF who developed RHD in cases of
MVR as well as MVL all had the DRB1*07 allele.
Conclusion
Our findings indicate that the HLA class II alleles DQB1*
and DRB1* are associated with a trend to risk/protection
relating to RF and the development of RHD. HLA class II
DRB1*07-DQB1*0401-2 and DRB1*07-DQB1*0302 can
be considered to be risk genotypes, while HLA class II
DRB1*06 and DQB1*0602-8 are probably protective.
Considering the association of the HLA-DRB1 and DQB1
genotype with RHD risk/protection, patients with
DRB1*07-DQB1*0401-2 are at risk of acquiring MVR, and
DRB1*07-DQB1*0302 patients are at risk of acquiring
MVL. By genotype analysis, we found that the RHD risk is
increased in individuals with DRB1*01-DQB1*0301-
DRB1*07-DQB1*0302 and DRB1*15-DQB1*0302-
DRB1*07-DQB1*0303 genotypes. As we mentioned
before, this conclusion is only a supposition, and study of a
larger group of patients would be required to confirm it.
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Table 6
Summary of HLA alleles or genotypes associated with
rheumatic heart disease
Allele associated with risk Allele associated with protection
DRB1*07 DRB1*06
DQB1*0401-2 DQB1*0602-8
DQB1*0302
DRB1*07-DQB1*0401-2 DRB1*06-DQB1*0602-8
DRB1*07-DQB1*0302
DRB1*01-DQB1*0301
DRB1*07-DQB1*0302
DRB1*15-DQB1*0302
DRB1*07-DQB1*0303
An asterisk preceding the allele number indicates the allele molecular
designation (typing at DNA level). Boldface type highlights association
cross-validated in this study.The genotype DRB1*06-DQB1*0602-8 may be associ-
ated with protection against RF and the development of
RHD.
It is significant that the patients were grouped into clini-
cally homogeneous groups as opposed to the total RF
patient group, as the various subgroups differed in DQ
allele frequencies.
The severity of RF is probably associated with the
DRB1*07 allele and development of certain RHD may be
dependent on specific DQ alleles.
Our study provides further information about the hypothe-
sis that there is a genetic predisposition to RF and about
the protective immune responses in RHD. Further insight
into the molecular mechanisms of the disease will be a
useful tool for predicting the clinical outcome in RF
patients and may offer new means of and approaches to
treatment and prophylaxis design in the future.
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